Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Cardiology Clinics|August 9, 2005
Kidney disease and cardiovascular disease: implications of dyslipidemiaWilliam F Keane, Paulette A LyleAmerican Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 4, 2003
Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL studyWilliam F Keane, Paulette A Lyle, Contributions to Nephrology|June 1, 2011
Lipid abnormalities in patients with chronic kidney diseaseWilliam F Keane, Joanne E Tomassini, David R NeffJournal of Atherosclerosis and Thrombosis|October 26, 2012
Lipid abnormalities in patients with chronic kidney disease: implications for the pathophysiology of atherosclerosisWilliam F Keane, Joanne E Tomassini, David R NeffExpert Opinion on Pharmacotherapy|March 24, 2006
Losartan: lessons learned from the RENAAL studyShahnaz Shahinfar, Paulette A Lyle, Zhongxin Zhang, et al.Journal of Clinical Lipidology|April 11, 2017
Effects of MAT9001 containing eicosapentaenoic acid and docosapentaenoic acid, compared to eicosapentaenoic acid ethyl esters, on triglycerides, lipoprotein cholesterol, and related variablesKevin C Maki, George Bobotas, Mary R Dicklin, et al.Kidney International|August 26, 2004
Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathyAnupama Mohanram, Zhongxin Zhang, Shahnaz Shahinfar, et al.Clinical and Experimental Nephrology|September 30, 2006
Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL studyKiyoshi Kurokawa, Juliana C N Chan, Mark E Cooper, et al.Kidney International. Supplement|October 16, 2004
Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathyCharles M Alexander, Paulette A Lyle, William F Keane, et al.Kidney International. Supplement|July 17, 2003
Identification of persons at high risk for kidney disease via targeted screening: the NKF Kidney Early Evaluation ProgramWendy W Brown, Allan Collins, Shu-Cheng Chen, et al.Pageof 3